KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Change in Accured Expenses (2016 - 2025)

Vertex Pharmaceuticals has reported Change in Accured Expenses over the past 17 years, most recently at $105.8 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $105.8 million for Q4 2025, up 133.05% from a year ago — trailing twelve months through Dec 2025 was $148.5 million (down 30.25% YoY), and the annual figure for FY2025 was $148.5 million, down 30.25%.
  • Change in Accured Expenses for Q4 2025 was $105.8 million at Vertex Pharmaceuticals, up from $83.9 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for VRTX hit a ceiling of $622.0 million in Q3 2024 and a floor of -$437.8 million in Q4 2022.
  • Median Change in Accured Expenses over the past 5 years was $69.7 million (2023), compared with a mean of $56.5 million.
  • Biggest five-year swings in Change in Accured Expenses: skyrocketed 1267.91% in 2022 and later plummeted 676.76% in 2024.
  • Vertex Pharmaceuticals' Change in Accured Expenses stood at $84.1 million in 2021, then crashed by 620.57% to -$437.8 million in 2022, then surged by 112.68% to $55.5 million in 2023, then plummeted by 676.76% to -$320.1 million in 2024, then soared by 133.05% to $105.8 million in 2025.
  • The last three reported values for Change in Accured Expenses were $105.8 million (Q4 2025), $83.9 million (Q3 2025), and -$63.2 million (Q2 2025) per Business Quant data.